Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas. Show more